Cerberus Ventures Research
Investment Thesis
Cerberus Ventures is the early-stage venture platform of Cerberus Capital Management, the $70B AUM alternative asset manager founded in 1992. Operating under the banner "Be Significant. Shape the Future," the team partners with visionary founders who are "challenging assumptions to transform industries and society for the better," with a stated focus on "consequential companies that address high-stakes problems." The platform's strategy centers on real-world, hard-technology assets — spanning defense-adjacent hardware, AI infrastructure, energy, quantum computing, and biotechnology — rather than pure software plays. As part of the larger Cerberus platform, the venture team explicitly leverages the firm's operating capabilities, government and industry network, and multi-platform resources (credit, private equity, real estate, supply chain) as a differentiator beyond capital alone.
Stage Focus
Cerberus Ventures invests from Pre-Seed/Seed through Series A and B, with selective support beyond early stage for breakout portfolio companies (e.g., follow-on reserves). Observed rounds range from a $4M seed (Photon Queue, Virchow Medical) to a $65M Series A (Star Catcher).
Check Size
Not publicly disclosed. Observed round sizes the firm has participated in or led range from roughly $4M to $65M, consistent with seed-to-Series-B stage focus.
Lead Tendency
Mixed. The firm has led rounds (Riven Systems pre-seed, Virchow Medical seed, Ansa Biotechnologies Series B) and co-led or participated in others (Star Catcher Series A co-lead with B Capital and Shield Capital; Layup Parts, AquaPoro, and Photon Queue as a participating investor).
Recent Activity
Cerberus Ventures launched its inaugural fund, Cerberus Venture One, with a $74.72M first close announced April 11, 2025. The fund is actively deploying, with a steady cadence of new investments through 2025 and 2026: Ansa Biotechnologies (Series B, DNA synthesis), Virchow Medical (seed, precision oncology), Layup Parts (Series A, composite manufacturing), Star Catcher (Series A, space-based power), AquaPoro (seed, atmospheric water generation), Photon Queue (seed, quantum memory hardware), and Riven Systems (pre-seed, AI-driven critical minerals processing, announced August 13, 2026 — the most recent disclosed deal).
Portfolio Highlights
Notable portfolio companies span the firm's five core verticals (Intelligence, Energy & Resources, Essential Infrastructure, Computing, Bio): Ansa Biotechnologies (synthetic DNA), Maybell Quantum (quantum computing infrastructure/dilution refrigerators), Lightsynq (photonic quantum interconnects, subsequently acquired by IonQ), Nudge Security (SaaS security posture management), Star Catcher (space-based optical power beaming), PrismML (1-bit edge AI models, spun out of Caltech research), Syntis Bio (clinical-stage obesity therapeutics, dosed first patient in its Phase 1/1b trial in March 2026), Virchow Medical (biopsy specimen stewardship for precision oncology), Layup Parts (composite parts manufacturing marketplace, founded by an ex-Anduril engineer), Photon Queue (room-temperature quantum memory), AquaPoro (atmospheric water generation), and Riven Systems (AI-driven critical minerals processing). Frequent co-investors include Founders Fund, Lux Capital, Marlinspike, Shield Capital, B Capital, Playground Global, Fall Line Capital, and Breakout Ventures.
Team
- Chris Darby, Global Head — Former President & CEO of In-Q-Tel (the CIA's venture arm) for 17 years; previously CEO of Sarvega (acquired by Intel) and Chairman/CEO of @stake (acquired by Symantec).
- Michael Rolnick, Senior Managing Director — Former CEO of Chain Bridge I (SPAC); previously managing general partner at ComVentures and senior operating roles at E*TRADE, News Corp, and PlayStudios. Multi-time Forbes Midas List honoree.
- Morgan Mahlock, Managing Director — Former investor at In-Q-Tel; focuses on quantum computing, cybersecurity, and application-layer AI.
- Sarah Istel, Managing Director — Former Deputy General Counsel, U.S. Senate Select Committee on Intelligence; focuses on multi-stage deep-tech defense across energy, biotech, and maritime.
- Dave LoBosco, Managing Director — Former Chief Technology Architect at In-Q-Tel and Chief Engineer at Orbital Sciences.
- Chenny Zhang, Managing Director — Former Principal at In-Q-Tel; leads biotechnology investing and sits on the boards of Ansa Biotechnologies and Virchow Medical.
- Laura Bocek, Vice President — Former AI/robotics investor at Toyota Research Institute; focuses on full-stack AI, cybersecurity, and robotics.
- Aidan Bruno, Analyst — Prior venture analyst experience at Rho Capital Partners; biotech background.
- Josh Heatley, Analyst — Startup operating experience plus a Cerberus Private Equity internship.
Decision Process
Small, partnership-driven investment team (roughly half a dozen investors plus analysts and operations support) reporting to Global Head Chris Darby. Investment decisions draw on backgrounds in company-building, technology, investing, and national security rather than a single generalist screen.
Founder Preferences
The team favors technically deep, mission-driven founders tackling hard, high-stakes problems in defense-adjacent and deep-tech categories — several team members previously sourced and evaluated deals at In-Q-Tel, the CIA's venture arm, and the portfolio skews toward dual-use hardware, AI, energy, and biotech rather than consumer or traditional enterprise software.
Geographic Focus
Primarily North America, with selective investment activity in Europe. Headquartered in New York, NY, alongside Cerberus Capital Management's corporate offices.